Early verdicts are not final verdicts, so no one is saying Amarin is doomed just two months into the launch of its prescription-grade fish oil pill. But right now, weekly Vascepa prescription growth is decelerating at a time when it should be doing the opposite. The number of patients going back for Vascepa refills is also lower than expected.
Amarin shares fell 3.5% to $7.36 in Monday trading. The stock is trading just slightly higher than its 52-week low of $7.30 -- a reflection of investor concern about the trajectory of the Vascepa launch.
Let's take a look at the prescription numbers, according to IMS Health. The latest figures are for the week ended March 15.Total Vascepa prescriptions were 1,240, up 14% from the week of March 8. Numerically, Vascepa scripts are growing but the rate of growth has dropped for four weeks straight. Week-over-week script growth was 33% for the week ended Feb. 22, down to 14% for the week of March 15. There is no "right" rate of growth for a new drug launch but this early, investors definitely want to see accelerating script growth. Deceleration at this stage of the launch is an uneasy sign. Amarin is offering incentives to doctors and patients in the form of free Vascepa samples and discounts, which is likely affecting script numbers. How much can't be quantified. Refill rates can only be estimated from weekly IMS data, but again, the numbers don't work in Amarin's favor. For the week of Feb 15 (still really early in the launch), total (560) and new (555) Vascepa scripts were essentially the same. This means just about every patient was new on Vascepa. Fast forward one month to March 15. At this point, patients prescribed Vascepa in mid-February should be going back to their pharmacy for another bottle, so ideally, the the difference between total and new prescriptions should be close to 500 for the week of March 15. The actual difference between total and new Vascepa scripts for March 15 is 141, suggesting a good number of patients didn't come back for a refill. Amarin was forced to launch Vascepa on its own in late January after a marketing partner failed to materialize. -- Reported by Adam Feuerstein in Boston. Follow @AdamFeuerstein
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV